18F-FDOPA PET in Neuroendocrine Tumours

• Status: Available
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Neuroendocrine tumours (NETs) are a group of neoplasms generally arising from the gastroenteropancreatic tract. They are usually slow growing, have low malignant potential, and often go unnoticed until they become metastatic. The correct treatment approach is dependent on the extent of the disease, however surgical approaches and systemic therapy can be curative.

Combined positron emission tomography/computed tomography (PET/CT) using the radiotracer 18F-6-L-fluorodihydroxyphenylalanine (18F-FDOPA) has been shown to be a promising non-invasive technique to help localizing NETs and guide their treatment.

Details

• Lead Sponsor: British Columbia Cancer Agency
• Treatments: Dihydroxyphenylalanine

Criteria

Inclusion Criteria

• Patients who meet the BCCA approved clinical indications for 18F-FDOPA PET/CT scans in neuroendocrine tumours.

• ECOG performance status 0 - 3.

• Able to provide written informed consent (or consent by guardian for subjects <19 years).

• Referred by a treating BC physician.

• Patients must be able to tolerate the physical/logistical requirements of completing a PET scan including lying flat for up to 40 minutes and tolerating intravenous cannulation for injection.

Exclusion Criteria

• Pregnancy.

• Patients who are medically unstable eg. acute cardiac or respiratory distress, hypotensive

• Patients who exceed the safe weight limit of the PET/CT bed (204.5 kg) or who cannot fit through the PET/CT bore (diameter 70 cm).